Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MNKD-501
- Development stage
- Preclinical
- Lead developer
- Mannkind
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
**MNKD-501** is an investigational dry powder inhaled formulation of FBM5712, a small molecule inhibitor of ALK-5 kinase (the TGF-β receptor kinase), developed by MannKind Corporation in collaboration with Thirona Bio for fibrotic lung diseases. It blocks pro-fibrotic TGF-β signaling to prevent tissue scarring, leveraging MannKind's Technosphere inhalation technology for sustained lung delivery, as demonstrated in rat pharmacokinetic studies showing prolonged local concentrations. Preclinical pharmacodynamics studies were planned for 2022, with potential for MannKind to license for clinical advancement if successful.[1][3][7]
- Other names
- FBM5712 (inhaled dry powder formulation)
02
Targets
TGFBR1
Beyond the preview
Go deeper on MNKD-501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MNKD-501.